PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 270 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,149,222 | -18.6% | 265,620 | +6.3% | 0.80% | -13.1% |
| Q2 2023 | $10,014,294 | -4.7% | 249,920 | -3.0% | 0.92% | -6.5% |
| Q1 2023 | $10,509,391 | -1.6% | 257,520 | -6.9% | 0.98% | -1.2% |
| Q4 2022 | $10,679,140 | -24.0% | 276,590 | +4.6% | 0.99% | -28.7% |
| Q3 2022 | $14,059,000 | -31.0% | 264,315 | -24.4% | 1.39% | -12.7% |
| Q2 2022 | $20,388,000 | -15.8% | 349,700 | +10.2% | 1.60% | -1.9% |
| Q1 2022 | $24,226,000 | +22.8% | 317,425 | -3.2% | 1.63% | +48.0% |
| Q4 2021 | $19,727,000 | -43.4% | 327,850 | -47.3% | 1.10% | -46.9% |
| Q3 2021 | $34,838,000 | -11.2% | 622,100 | -3.8% | 2.07% | -9.8% |
| Q2 2021 | $39,231,000 | -7.2% | 646,530 | +7.2% | 2.30% | -9.5% |
| Q1 2021 | $42,254,000 | +18.2% | 602,860 | +1.0% | 2.54% | +7.0% |
| Q4 2020 | $35,733,000 | +37.7% | 597,145 | +38.3% | 2.37% | +11.0% |
| Q3 2020 | $25,954,000 | – | 431,700 | – | 2.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |